Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 13/20 | 0.56 |
| ▸ | JAK2 | O60674 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 4/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30882695 | 1.00 | PDPK1 (0.56) | PDPK1JAK2GAAKDM4ECYP3A4 | |
| Hydrochloric Acid SCHEMBL7425346 | 0.98 | PDPK1 (0.55) | PDPK1JAK2GAAKDM4ECYP3A4 | |
| SCHEMBL27623383 | 0.86 | JAK2 (0.68) | PDPK1JAK2ROCK1FGFR1FGFR2 | |
| SCHEMBL7214708 | 0.85 | JAK2 (0.56) | PDPK1JAK2GAAKDM4ECYP3A4 | |
| SCHEMBL2144862 | 0.83 | PDPK1 (0.59) | PDPK1JAK2GAAKDM4ECYP3A4 | |
| SCHEMBL91579 | 0.83 | PDPK1 (0.55) | PDPK1JAK2GAAKDM4ECYP3A4 | |
| Hydrochloric Acid SCHEMBL7214665 | 0.83 | JAK2 (0.55) | PDPK1JAK2GAAKDM4ECYP3A4 | |
| SCHEMBL12124008 | 0.81 | GAA (0.43) | PDPK1JAK2GAAROCK1PKM | |
| SCHEMBL7220524 | 0.81 | GAA (0.43) | PDPK1JAK2GAAROCK1PKM | |
| SCHEMBL26977245 | 0.80 | PDPK1 (0.51) | PDPK1JAK2GAAKDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
| US-7265220-B2 | Amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | LES LABORATORIES SERVIER (FR) | 2007-09-04 | — | — | US | disclosed |
| EP-1706396-A1 | N-(4-CARBAMIMIDOYL-BENZYL)-2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA | F.HOFFMANN-LA ROCHE AG (CH) | 2006-10-04 | — | — | EP | disclosed |
| US-7056932-B2 | Heterocyclyl substituted 1-alkoxy acetic acid amides | HOFFMAN-LA ROCHE INC. (US) | 2006-06-06 | — | — | US | disclosed |
| CN-1257889-C | Novel amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2006-05-31 | — | — | CN | disclosed |
| WO-2005058868-A1 | N-(4-CARBAMIMIDOYL-BENZYL) -2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| CN-1633412-A | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | SERVIER LAB (FR) | 2005-06-29 | — | — | CN | disclosed |
| US-20050137168-A1 | Heterocyclyl substituted 1-alkoxy acetic acid amides | HOFFMANN-LA ROCHE INC. | 2005-06-23 | — | — | US | disclosed |
| US-20050085517-A1 | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | LES LABORATOIRES SERVIER (FR) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PDPK1 1823/4885JAK2 2680/4885GAA 1534/4885 |
| US-20050137168-A1 | Heterocyclyl substituted 1-alkoxy acetic acid amides | F12, TFPI, F11 | PDPK1 3627/4885JAK2 552/4885GAA 795/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PDPK1 1823/4885JAK2 2680/4885GAA 1534/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PDPK1 1823/4885JAK2 2680/4885GAA 1534/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PDPK1 1823/4885JAK2 2680/4885GAA 1534/4885 |
| US-20050085517-A1 | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | ARGLU1, PNISR, ATIC | PDPK1 4275/4885JAK2 656/4885GAA 3452/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PDPK1 2021/4885JAK2 2848/4885GAA 1292/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PDPK1 1823/4885JAK2 2680/4885GAA 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.